Racotumomab therapeutic vaccine in an elderly with advanced lung cancer
Keywords:
elderly, non-small cells lung cancer, therapeutic vaccine, racotumomab, phase III clinical trial, survival.Abstract
The case report of a 84 years elderly smoker, is presented with diagnosis of lung cancer in stage IV who was included in the phase III clinical trial to be treated with racotumomab. Clinical improvement and recovery of the patient's general state was observed, because according to the functional scale the study concluded with ECOG 0. Therefore, it is opportune to highlight that this vaccine increases the survival of those affected by recurrent non-small cells lung cancer or in advanced stages.
Downloads
References
2. Zalduendo P. Cáncer de pulmón. Síntomas, tipos, tratamiento y esperanza de vida, 2016 [citado 16/08/2019]. Disponible en: https://www.enfermedadesgraves.com/blog/cancer-de-pulmon/
3. Luz Hernández K de la, Rabasa Y, Montesinos R, Fuentes D, Santo Tomás JF, Morales O, et al. Cancer vaccine characterization: from bench to clinic. Vaccine. 2014; 32(24):28518
4. Noriega L, Bares JP, García E, Ruíz Valdés M, Loo Y, González I, et al. Factores de riesgo y tamizaje del cáncer de pulmón de células no pequeñas (CPCNP): 2do Consenso Nacional de la Sociedad Panameña de Oncología (Mesa 1). Rev Med Panamá. 2017 [citado 19/02/2019];37(1). Disponible en: http://www.revistamedica.org/index.php/rmdp/article/view/427/0
5. Wang Q, Huang H, Zeng X, Ma Y, Zhao X, Huang M. Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials. PeerJ. 2016 [citado 19/02/2019]; 4. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27781159
6. Pérez Escobar MM, García Rodríguez ME, Armas Moredo K, Álvarez Montané I, Oliva Díaz JA, Pérez Escobar E. Cáncer de pulmón de células no pequeñas: presentación de caso. AMC. 2017 [citado 03/07/2019];21(2). Disponible en: http://www.revistaamc.sld.cu/index.php/amc/article/view/4798
7. Gabri MR, Cacciavillano W, Chantada GL, Alonso DF. Racotumomab for treating lung cancer and pediatric refractory malignancies. Expert OpinBiol Ther. 2016 [citado 03/07/2019]; 16(4). Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26903265
8. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25): 2380-8.
9. Cobián Caballero CO, Acosta Brooks SC, Martínez Feria F, Romero García LI. Supervivencia en pacientes con cáncer pulmonar de células no pequeñas vacunados con CIMAvax-EGF. MEDISAN. 2016 [citado 27/06/2016];20(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192016000300007&lng=es
10. Hernández AM, Rodríguez N, González JE, Reyes E, Rondón T, Griñán T, et al. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol. 2011;186(6):3735-44.
Published
How to Cite
Issue
Section
License
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
Guidelines for authors
